Table 1.

Main characteristics of including studies.

Author	Year	Type	Intervention & control		Patient number		Median age (y)		Gender (M/F)		Gastrectory (%)		Outcome measures
			Taxane group	Control group	Taxane group	Control group	Taxane group	Control group	Taxane group	Control group	Taxane group	Control group
Kilickap	2011	nRCT	DCF	CF	40	36	53/18–70	52/23–70	24/16	18/18	35	40	OS, PFS, ORR, Safety
Koizumi	2014	RCT	DS	S-1	314	321	65/23–79	65/27–79	227/87	229/92	NM	NM	OS, PFS, ORR, Safety
Kos	2011	nRCT	DCF	CF	40	30	52.5/23–68	54.5/35–69	29/11	19/11	NM	NM	OS, PFS, ORR, Safety
Wang	2014	nRCT	DS	SOX	36	48	55.5/33–72	60/35–76	20/16	34/14	NM	NM	OS, PFS, ORR, DCR, Safety
Guo	2015	nRCT	DS	SOX	101	87	60/20–78	56/37–77	59/42	61/26	NM	NM	OS, PFS, ORR, DCR, Safety
Mochiki	2012	RCT	SPac	CiS	42	41	NM	NM	31/11	30/11	21	20	OS, PFS, RR, Safety
Roth	2007	RCT	DCF	ECF	41	40	61/35–78	59/32–71	30/41	30/40	32	18	ORR, Safety
Sugimoto	2014	RCT	SPac	SIri	51	51	62/30–75	64/25–75	28/13	28/13	NM	NM	OS, PFS, ORR, Safety
Teker	2014	nRCT	DCF	ECF	42	44	54/25–72	57/30–77	21/21	28/16	NM	NM	OS, PFS, ORR, Safety
Cutsem	2006	RCT	DCF	CF	221	224	55/26–79	55/25–76	159/62	158/66	NM	NM	TTP, OS, ORR, Safety
Wang	2013	RCT	SPac	S-1	41	41	63/35–74	61/31–73	32/9	30/11	30	32	OS, PFS, ORR, Safety

RCTs: randomized controlled trials, nRCT: non-randomized controlled trials. DCF: Docetaxle, Cisplatin and Fluorouracil; CF: Cisplatin and Fluorouracil; DS: Docetaxel and S-1; SOX: Oxaliplatin and S-1; SPac: Paclitaxel and S-1; CiS: Cisplatin and S-1; ECF: Epirubicin, Cisplatin and Fluorouracil; SIri: Irinotecan and S-1; NM: not mentioned; OS: overall survival; PFS: progression-free survival; ORR: overall response rate; DCR: disease control rate. The quality of RCT were assessed by the Cochrane risk of bias tool, and the quality of nRCT were assessed by Newcastle–Ottawa Scale.